Abstract
COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has reached pandemic proportions with negative impacts on global health, the world economy and human society. The clinical picture of COVID-19, and the fact that Angiotensin converting enzyme 2 (ACE2) is a receptor of SARS-CoV-2, suggests that SARS-CoV-2 infection induces an imbalance in the renin-angiotensin system (RAS). We review clinical strategies that are attempting to rebalance the RAS in COVID-19 patients by using ACE inhibitors, angiotensin receptor blockers, or agonists of angiotensin-II receptor type 2 or Mas receptor (MasR). We also propose that the new MasR activator BIO101, a pharmaceutical grade formulation of 20-hydroxyecdysone that has anti-inflammatory, anti-fibrotic and cardioprotective properties, could restore RAS balance and improve the health of COVID-19 patients who have severe pneumonia.
【초록키워드】 COVID-19, SARS-CoV-2, ACE2, coronavirus, pandemic, Anti-inflammatory, SARS-COV-2 infection, angiotensin converting enzyme 2, severe acute respiratory syndrome Coronavirus, ACE inhibitors, angiotensin converting enzyme, RAS, Angiotensin receptor blockers, global health, renin-angiotensin system, Health, clinical picture, Impact, 20-hydroxyecdysone, receptor, severe pneumonia, angiotensin, COVID-19 patient, Imbalance, acute respiratory syndrome, Renin, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, enzyme, agonist, agonists, Rebalance, IMPROVE, caused, proportion, induce, reached, 【제목키워드】 Respiratory failure, drug, Protective, Potential treatment, COVID-19 patient, Developing, activate,